Navigation Links
Drug Proves Effective in Slowing Melanomas
Date:4/15/2008

Riluzole, used to treat Lou Gehrig's disease, inhibits aggressive growth, study finds

TUESDAY, April 15 (HealthDay News) -- The drug riluzole, approved in the United States to treat amyotrophic lateral sclerosis (ALS), slows the growth of highly aggressive melanoma skin cancer, according to a new study.

A common feature of both melanoma and ALS (also called Lou Gehrig's disease) is an excess amount of the protein glutamate, a cellular growth factor or food for cells. Too much glutamate can overstimulate neurons to the point where they burn out -- a possible explanation for what happens in ALS, according to background information in the study. Overproduction of glutamate causes the growth and expansion of melanoma.

Riluzole (brand name Rilutek) inhibits the release of glutamate.

In laboratory tests using cultures of human melanoma cell lines, researchers at Rutgers University and the Cancer Institute of New Jersey found that riluzole appeared to switch off overproduction of glutamate and slow the growth rate of the melanoma cells. In tests on animals, the drug showed the same suppression of melanoma cell growth.

The researchers then started testing the drug on 11 people with late-stage (stage 3 or 4) melanoma. The patients in this phase 0 (exploratory, first-in-humans) trial received riluzole for two weeks.

"Our preliminary results show three solid positive responses in nine of the patients who had been able to complete the trial to date," Dr. James Goydos, a surgical oncologist at the Cancer Institute of New Jersey, said in a prepared statement.

Other patients in the group showed some indications of responding to the drug, and they'll be reassessed at the end of the trial.

The research was to be presented April 15 at the annual meeting of the American Association for Cancer Research, in San Diego.

The findings provide "enough data to show that we should go on to a more extensive (phase 1/2) trial," Goydos said. He expects it will begin later this year and include 50 to 100 patients with stage 4 melanoma.

"I think this drug is going to be extremely important as an adjunct to surgical treatment of stage 3 or stage 4 melanoma," Goydos said. "The challenge is to keep it from recurring, which has happened in patients on the order of 50 percent. With low toxicity likely, riluzole could potentially be given for long periods of time to slow down the metabolic process responsible for the disease's recurrence."

More information

The U.S. National Cancer Institute has more about melanoma.



-- Robert Preidt



SOURCE: Rutgers University, news release, April 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. Nasal Anthrax Vaccine Proves Effective in Animal Study
3. FDA Approves New Roche West Nile Virus Blood Screening Test
4. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
5. Exercise and yoga improves quality of life in women with early-stage breast cancer
6. Toddler Study Proves Humans Outsmart Apes
7. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
8. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
9. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
10. FDA Approves SOMA(R) (carisoprodol) 250 mg
11. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... gain site attention and engagement over the household brands of Top-20 pharma by ... will discuss how partnering with the right outsourcing payments provider can provide the ...
(Date:3/27/2017)... Boston, MA (PRWEB) , ... March 27, 2017 ... ... NEJM Group, the organization behind the New England Journal of Medicine and NEJM ... , NEJM Knowledge+ Pediatrics Board Review was created by a panel of pediatricians ...
(Date:3/27/2017)... Orion, Michigan (PRWEB) , ... March 27, 2017 ... ... results. The comprehensive weight management program at Women’s Excellence will help patients ... initial evaluation and physical exam. The specialists at Women's Excellence will measure ...
(Date:3/27/2017)... ... March 27, 2017 , ... Janet Schloz is still in shock after receiving a ... I’ve had in a long time,” she said. , She thinks the coming week is ... I never thought I would have to help my students.” , The award will allow ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending ... the pending litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil ... am thrilled to announce that we have now reached a settlement agreement regarding ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 FinancialBuzz.com News Commentary  ... According to a new report ... North America , grew 34 percent to $6.7 billion and can ... of (CAGR) over the next five years, from $6.7 billion in 2016, ... Americans that will be able to purchase cannabis without a doctor,s recommendation. ...
(Date:3/27/2017)... March 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), ... address serious pulmonary diseases, today announced that it has added ... fibrosis and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the ... Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... March 27, 2017 The global ... USD 16.0 billion by 2025, according to a new ... of chronic diseases is anticipated to be responsible for ... thereby widens the scope for growth during the forecast ... population, which is highly susceptible to chronic diseases, is ...
Breaking Medicine Technology: